Invasive aspergillosis (IA) remains a major cause of morbidity and mortality following solid organ transplantation. To assess the incidence of IA following lung transplantation and to identify risk factors for its occurrence, we performed a case-control study involving 101 patients undergoing lung transplantation at our institution from 1990 to 1995 and reviewed the findings. Fourteen patients (14%) developed IA. The mean time from transplantation to diagnosis was 15 months. Nine patients died; the mean time to death from diagnosis was 13 days. Risk factors associated with developing IA included concomitant cytomegalovirus (CMV) pneumonia or viremia and culture isolation of Aspergillus species from a respiratory tract specimen after lung transplantation. Optimal strategies to prevent IA in lung transplant recipients remain to be determined, but prevention of aspergillus airway colonization and CMV viremia and disease after transplantation may be important targets for prophylactic interventions.
Since the first successful lung transplantation in 1983, ú6,000 lung transplantations have been performed, including
Definitive IA was defined as culture isolation of Aspergillus 953 in the United States in 1996 [1, 2] . Infectious complications species together with histopathologic evidence of tissue invaremain a major cause of morbidity and mortality, responsible sion during either biopsy or postmortem examination. The presfor Ç31% of deaths occurring 60 days after transplantation ence of septate hyphae with dichotomous branching at 45Њ [1] . Aspergillosis is a major problem, occurring in up to 15% angles within tissue was considered histological evidence of of patients following lung transplantation [3 -6] . We report our aspergillosis. Probable pulmonary IA was defined as a characexperience with invasive aspergillosis (IA) in lung transplant teristic clinical and radiographic picture (nodular or cavitary recipients at The Cleveland Clinic Foundation and examine lesions on a chest radiograph) with either histopathologic evirisk factors associated with this complication. dence of tissue invasion or culture of a respiratory tract specimen that yielded Aspergillus. Disseminated aspergillosis was defined as the presence of extrapulmonary disease.
Materials and Methods
The diagnosis of CMV pneumonia was established by the The Cleveland Clinic Foundation lung transplantation prorecognition of cytomegalic inclusion bodies in tissue. CMV gram was begin in 1990, and details regarding the program have infection was defined as isolation of CMV from blood (virebeen reported previously [7] . Prophylaxis for cytomegalovirus mia), respiratory secretions (bronchoalveolar lavage fluid), or (CMV) infection was used for all lung transplant recipients urine in the absence of recognition of inclusion bodies in tissue. except those CMV-seronegative patients who had received an CMV infection was considered concomitant if it occurred organ from a CMV-seronegative donor. All patients received within 30 days of the diagnosis of IA. primary chemoprophylaxis for Pneumocystis carinii infection.
The clinical diagnosis of acute lung rejection was based on Following transplantation, patients were not housed in areas the clinical presentation, characteristic radiographic changes, with laminar air flow or high-efficiency particulate filters.
absence of infection, and results of lung biopsy. No other significant differences between cases and controls were identified regarding any other potential risk factors studied, including underlying disease, concomitant organ rejection, Results CMV serological status of donor and recipient, or double vs. single lung transplantation.
Incidence of IA
We identified 14 lung transplant recipients with definitive or probable IA during the 5-year study period (93 cases per Discussion 1,000 patient-transplant -years) (figure 1). Eight patients had definite IA, and six had probable IA. Two patients had ulceraPrevious studies have documented high rates of pulmonary tive tracheobronchitis at their bronchial anastomotic sites, and IA following lung transplantation. Our attack rate of 14% disseminated disease (brain abscesses and skin infection) ocamong 101 lung transplant recipients is within the range of curred in three.
3.4% to 16% that was reported by five different institutions The mean interval from transplantation to diagnosis of IA studying 446 patients [5, 9 -12] . We identified concomitant was 15 months (range, 29 days to 5 years). All lung transplant CMV pneumonia or infection and culture isolation of Aspergilrecipients with IA had Aspergillus recovered from at least one lus from a respiratory tract specimen after lung transplantation clinical specimen after transplantation. The mortality rate assoas significantly associated with an increased risk of IA. An ciated with IA was 64%, with a mean interval from diagnosis association between aspergillosis and CMV infection in lung to death of 13 days (range, 0 -30 days). For the nine patients transplant recipients has been reported previously [5] . with pulmonary IA who died, the mean survival after the first A major consequence of CMV infection in solid organ transpositive culture was 13 days (range, 1 -187 days).
plant patients is a higher risk of opportunistic superinfection Concomitant CMV infections (positive cultures of buffy coat because CMV itself is an immunomodulator [13] . CMV infecspecimens) occurred in eight lung transplant recipients with IA tion is an independent risk factor for the development of other (57%), three of whom also had CMV pneumonia. One addisystemic infections in liver transplant recipients [14] , heart tional patient with IA had CMV retinitis without CMV pneutransplant recipients [15] , and renal allograft recipients [16] . monia or a buffy coat specimen positive for CMV.
The precise mechanisms for the immunosuppression associated with CMV infection are unknown but involve lymphocyte suppression with reversal of the helper-suppressor cell ratio and suppressed function of natural killer cells [17] .
In conclusion, IA remains a devastating disease in organ transplant recipients, especially lung transplant recipients. Concomitant CMV infection is a risk factor for IA in lung transplant recipients. Optimal strategies to prevent IA in lung transplant recipients remain to be determined, but prevention of Aspergillus airway colonization and CMV viremia and disease after transplantation may be important targets for prophylactic interventions. 
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